RTW Biotech Opportunities (RTW) has provided an update on private portfolio company Corxel Pharmaceuticals, its second-largest core holding as at 31 May 2025, representing 8.3% of NAV. Corxel, a clinical-stage biopharma firm developing therapies for cardiometabolic diseases, recently announced two key developments relating to its lead candidate, CX11 – an investigational, once-daily oral GLP-1 receptor … Continue reading RTW Biotech Opportunities’ Corxel Pharmaceuticals makes clinical progress